Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cybin Inc. Common Shares (NY:CYBN)

8.250 +0.780 (+10.44%)
Streaming Delayed Price Updated: 3:56 PM EDT, May 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
39 40 Next >
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Presents CYB003 Preclinical Data Amongst Leading Scientists, Academics in Neuropsychopharmacology
Via Investor Brand Network
Seelos Therapeutics, Numinus Wellness Among Top Psychedelic Movers Of Today
Via Benzinga
Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting
From Cybin Inc.
Via Business Wire
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Major Psychedelic Drug Stocks Went Up 7% This Week; Still Down 46% YTD
The 6 major psychedelic stocks researching the treatment of a variety of mental illnesses were UP 7% this week and are UP 3 % in the last 6 weeks. The 6 therapy clinic stocks went UP 3% this week and... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From December 2, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 1, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From November 30, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 72 companies hit new 52-week lows. 
Via Benzinga
Revive Therapeutics, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 107 stocks hit new 52-week lows. 
Via Benzinga
Cannabis Category Performances Last Week Ranged From +5.2% To -2.3%
The 5 categories in the cannabis sector perform quite differently week to week and last week was no exception. This article is a summary of how each category performed last week, in descending order... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From November 25, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From November 24, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From November 23, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From November 22, 2022
Via Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 21, 2022
Via Benzinga
Psychedelic Drug Stocks Index Continued To Decline Last Week
This article highlights the performances of the 6 constituents in the munKNEE Psychedelic Drug Stocks Index last week and in the last 3 weeks and the extent to which each company is likely to encounter... 
Via Talk Markets
Biomind Labs, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From November 16, 2022
Via Benzinga
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Cybin Shares Q2 Financial & Business Results, Focus On Licensing Deals For Preclinical Assets
Cybin Inc. (NYSE: CYBN) reported its unaudited financial results for its second quarter ended September 30, 2022, and provided business highlights for the period. 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Q2 Results, Recent Business Highlights, Presentation of CYB003 Preclinical Data at Neuroscience 2022
Via Investor Brand Network
Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022
From Cybin Inc.
Via Business Wire
Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Retirement
Exposures Pension Product Safety
Clinical Stage Psychedelic Stock Index Up 6%; Therapy Clinic Stocks Down 8%
We highlight the performance of our Psychedelic Drug Stocks Index and the 6 psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of different psychedelic... 
Via Talk Markets
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.